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Abstract
Background: Many oldest-old (> 80-years) with multimorbidity and polypharmacy are at high risk of inappropriate
use of medication, but we know little about whether and how GPs would deprescribe, especially in the frail oldest-
old. We aimed to determine whether, how, and why Swiss GPs deprescribe for this population.
Methods: GPs took an online survey that presented case-vignettes of a frail oldest-old patient with and without
history of cardiovascular disease (CVD) and asked if they would deprescribe any of seven medications. We
calculated percentages of GPs willing to deprescribe at least one medication in the case with CVD and compared
these with the case without CVD using paired t-tests. We also included open-ended questions to capture reasons
for deprescribing and asked which factors could influence their decision to deprescribe by asking for their agreement
on a 5-point-Likert-scale.
Results: Of the 282 GPs we invited, 157 (56%) responded: 73% were men; mean age was 56. In the case-vignette
without CVD, 98% of GPs deprescribed at least one medication (usually cardiovascular preventive medications) stating
it had no indication nor benefit. They would lower the dose or prescribe pain medication as needed to reduce side
effects. Their response was much the same when the patient had a history of CVD. GPs reported they were influenced
by ‘risk’ and ‘benefit’ of medications, ‘quality of life’, and ‘life expectancy’, and prioritized the patient’s wishes and
priorities when deprescribing.
Conclusion: Swiss GPs were willing to deprescribe cardiovascular preventive medication when it lacked indication but
tended to retain pain medication. Developing tools for GPs to assist them in balancing the risks and benefits of
medication in the context of patient values may improve deprescribing activities in practice.
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Background
General practitioners (GPs) often see oldest-old (>
80 years) and multimorbid patients [1, 2]. Multimorbid-
ity (> 3 chronic conditions) is strongly associated with
age and use of multiple medications [3]. In a random
sample of Swiss patients [4], 37% of those over 70 took 5
or more medications each day, meeting the common
definition of polypharmacy [5]; 44% of patients with
polypharmacy took at least one potentially inappropriate
medication [4]. Both polypharmacy and inappropriate
medication use can increase risk of adverse events in
older individuals, including adverse drug events (ADE)
[6, 7], medical errors [8], non-compliance, falls [9], im-
paired physical and cognitive function, hospitalization
[10], higher costs of care [11] and mortality [12].
Though these harms are well-established in cross-sec-
tional and longitudinal studies, health care professionals
do not have as much clear evidence about either the
benefits or safety of stopping or reducing inappropriate
medications (deprescribing) [13, 14]. Deprescribing is
‘the process of withdrawal of an inappropriate medica-
tion, supervised by a health care professional with the
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goal of managing polypharmacy and improving out-
comes’ [15]. Deprescribing can reduce ADEs and im-
prove patient quality of life and should be integrated
into clinical care [16, 17].
Recent reviews show that appropriately planned and
monitored deprescribing is feasible and safe [13, 18, 19]
but clinicians may be uncomfortable deprescribing for a
variety of reasons including fear of unknown negative
consequences of change, the existence of other pre-
scribers, and perceived patient/family expectations [20].
GPs also report that the lack of evidence-based clinical
practice guidelines can pose a barrier to deprescribing
[20–23]. Treatment guidelines rarely discuss when and
how medications should be deprescribed or clearly de-
scribe appropriate treatment of older adults with multi-
morbidity and polypharmacy [24–26]. The lack of
specific recommendations may be explained by a scar-
city of evidence, since older adults with multimorbidity
and polypharmacy are often excluded from the random-
ized controlled trials (RCTs) [27] that inform guideline
development.
GPs do have access to various tools that help them iden-
tify inappropriate medications or those suitable for depre-
scribing, such as lists of medications that may be
inappropriate for older adults (e.g., the Beers criteria [28]
and the STOPPFrail tool [26]), to implicit guides, and
overall processes for deprescribing. However, the useful-
ness (such as the relevance of PIMs lists to complex indi-
viduals) and feasibility (e.g. time taken to complete
complex review) of these in regular practice has not yet
been established [29]. Complex medical, social and ethical
situations also make this group harder to treat [30, 31].
Thus, deprescribing in frail oldest-old and multimorbid
patients with polypharmacy poses a challenge to GPs that
few studies have explored [32].
We used a survey with case-vignettes to determine
whether, how and why GPs deprescribe in frail oldest-
old patients with multimorbidity and polypharmacy, and
to identify factors that influenced their decision to
deprescribe.
Methods
Design
In the LESS Study (“Barriers and enabLers to willingnESs
to depreScribing in older patients with multimorbidity and
polypharmacy and their General Practitioners”) we report
the findings of a cross-sectional survey in Swiss GPs.
Participants
We set out to sample a group of GPs (N = 282) from all
regions of Switzerland who had taken part in earlier
case-vignette studies and were open to invitations to
participate in future research projects [33, 34]. We
included all respondents who were currently practicing
GPs in Switzerland.
Survey
We used the same method we employed previously to
describe GP decisions about antihypertensive treatment
in oldest-old patients [33, 34], and developed an online
survey with three sections (A-C): A) GP characteristics
and self-reported frequency of deprescribing in oldest-
old; B) two case-vignettes of frail oldest-old patients with
contrasting histories of CVD; and, C) questions designed
to identify factors that may have affected GPs’ decisions
to deprescribe. (See Additional file 1 for the complete
questionnaire).
For the case-vignettes in part B, our research team,
composed mostly of GPs, came to consensus on a sce-
nario that represented a typical patient seen in primary
care, and medications frequently prescribed to patients
≥70 years. We generated two fictitious case-vignettes
featuring an 82-year-old patient who presented to the
GP for a consultation. His frailty was indicated by se-
verely impaired physical and cognitive functions, a
last-recorded MMSE of 12/30, his residence in a nursing
home, and his complete dependency in activities of daily
living [35]. He was being treated with aspirin 100 mg
(once daily [od]), atorvastatin 40 mg (od), enalapril
10 mg (od), amlodipine 5 mg (od), paracetamol 1 g
(three times daily [tid]), tramadol 50 mg (twice daily
[bid]), and pantoprazole 20 mg (od). The survey asked
GPs which medications (if any) they would cease or re-
duce (both covered by the term ‘deprescribing’). The vi-
gnettes presented the same patient, but the second
added a positive history of CVD. We included an open-
ended question where we invited GPs to explain why
they chose to deprescribe that medication.
In Part C, we asked GPs to rate the importance of
sixteen factors that might influence their decision to
deprescribe (5-Point Likert-scales, ranging from “not
important” to “very important”). The factors were
drawn from the analyses of Anderson et al. [20], and
Luymes et al. [36]. An open-ended final question in-
vited participants to name other factors and make
additional comments.
To test for clarity and feasibility, we piloted the sur-
vey among five experienced GPs. Then sent invitations
via email to GPs and asked them to complete the an-
onymous online survey. Non-responders were sent up
to three email reminders. The study was conducted in
Switzerland at the Institute of Primary Health Care of
the University of Bern (BIHAM) between September
2017 and April 2018. It was approved by the Ethics
Committee of the Canton of Bern (reference number
2017–02188).
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Statistical analyses
First, we described GP characteristics by calculating pro-
portions, means and standard deviations (SD). Next, we
described the proportions of GPs deprescribing per
case-vignette and per medication by calculating crude
percentages and 95% confidence intervals (CI). We used
McNemar’s test to compare cases with positive and
negative history of CVD and calculated the mean num-
ber of medications GPs deprescribed. Then one author
(SM) analysed the content of the GPs’ free text explana-
tions for deprescribing medications. A senior author
(SS) reviewed her codes and themes and helped finalize
categories. Finally, we dichotomized Likert-scale re-
sponses to the questions in Part C into very important/
important and reported as percentages. We analysed the
content and coded responses to the final open-ended
question. We defined a two-sided p-value of < 0.05 as
significant. All analyses were performed with STATA
15.1 (StataCorp, College Station, TX, USA).
Results
GP characteristics
Of 282 GPs invited, 157 (56%) responded: 73% were
men; mean age was 56 (SD 8); and, half the participants
had > 25 years of experience in practice (Table 1). Most
GPs (88%) estimated that they “frequently” or “very fre-
quently” saw patients ≥70 years in their practice; 84% re-
ported they “frequently” or “very frequently” considered
deprescribing in their daily practice, but only 30% depre-
scribed “frequently” or “very frequently”.
Case-vignette analyses
In the case-vignette without CVD history, 153 GPs
(98%) reported they would deprescribe at least one
medication. On average, they would deprescribe 4.2
(95%CI 4.0–4.4) of the possible seven medications. In
the case-vignette with CVD history, a similar proportion
of GPs (97%) would deprescribe at least one medication;
on average, they would deprescribe 3.3 (95%CI 3.1–3.6)
medications (Table 2).
In the case-vignette without history of CVD, reported
willingness of participants to deprescribe was high for
cardiovascular preventive medications like atorvastatin
(100%) and aspirin (74%). Many GPs also reported that
they would deprescribe at least one of the antihyperten-
sive medications (44% selected amlodipine; 24% selected
enalapril), and 88% would deprescribe pantoprazole. Far
fewer GPs (29%) reported that they would deprescribe
paracetamol.
When we compared the case-vignette with CVD history
to the vignette without CVD, we found that 29% of GPs
would deprescribe paracetamol in both cases (p = 0.56) and
an almost equal percentage (70% vs. 71%, p = 0.71) would
deprescribe tramadol. For patients with CVD history, a
smaller percentage of GPs would deprescribe cardiovascu-
lar preventive medications like aspirin (32% vs. 74%, p <
0.001), atorvastatin (76% vs. 100%, p < 0.001), enalapril
(19% vs. 24%, p = 0.033), amlodipine (36% vs. 44%, p =
0.011), and pantoprazole (81% vs. 88% p = 0.002).
Reasons to deprescribe
When we categorized the reasons GPs gave for depre-
scribing in the frail oldest-old without CVD history we
found they most frequently deprescribed aspirin for ‘no
indication’ (36% of those who would deprescribe at least
one medication), enalapril (10%), amlodipine (14%), and
pantoprazole (73%). GPs gave ‘lack of benefit’ as the
main reason for deprescribing atorvastatin (37%). ‘Side
effects’ were the most common reason they would
deprescribe tramadol (50%). They were less likely to
deprescribe pain medication, especially paracetamol,
than cardiovascular medication and explained that they
Table 1 Baseline characteristics of participating GPs (n = 157)
Baseline characteristics
Female, n (%) 42 (27)
Age, years (SD) 56 (8)
Experience as GP, years (SD) 20 (9)
Number of consultations on average per working day, n (%)
< 15 12 (7)
15–25 67 (43)
26–35 61 (39)
> 35 17 (11)
How often do you see/treat patients > 70 with multimorbidity and
polypharmacy? n (%)
very rarely 1 (1)
rarely 3 (2)
occasionally 17 (11)
frequently 89 (57)
very frequently 46 (29)
How often do you deal with the topic of deprescribing medications in
your daily practice? n (%)
very rarely 0 (0)
rarely 0 (0)
occasionally 25 (16)
frequently 95 (61)
very frequently 36 (23)
How often do you deprescribe medications during consultations with
your patients in your daily practice? n (%)
very rarely 0 (0)
rarely 8 (5)
occasionally 101 (65)
frequently 39 (25)
very frequently 8 (5)
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would either reduce the dose (8%) or prescribe it as
needed (8%).
GPs reasons for deprescribing for the frail oldest-old
with CVD history were similar, except for atorvastatin
and aspirin. For these drugs, GPs mentioned other rea-
sons, including ‘no priority’, ‘not in >80 years’, and ‘not
appropriate prevention’.
Factors influencing deprescribing among GPs
GPs most commonly rated four factors as “important”
or “very important” in their decisions about deprescrib-
ing: ‘risk of a medication’ (99%); ‘benefit of a medication’
(98%); ‘quality of life’ (98%); and, ‘life expectancy of the
patient’ (96%) (Table 3). GPs considered the factors ‘ex-
penditure of time for deprescribing’ (19%) and ‘self-dis-
pensation of medication in GP office’ (which means in
Switzerland drug delivery by GPs in their own office)
(7%) to be much less important.
In their response to the open-ended question, many
GPs mentioned the importance of patients’ wishes and
priorities, and that their own ‘assessment of cost/benefit
of a medication’ and ‘drug interactions’ could influence
their decision to deprescribe.
Discussion
Summary
In a hypothetical frail oldest-old patient on 7 long-term
medications, GPs would deprescribe (cease or reduce
the dose of ) an average of 4 medications for patients
with no CVD history and 3 medications for patients with
CVD history. In either case, they would usually depre-
scribe cardiovascular preventive medication (statin, as-
pirin, blood pressure lowering medication) because they
thought it lacked indication or benefit. They would re-
tain pain medication, but might reduce it or prescribe it
“as needed” if they expected side effects. Positive CVD
history was associated with less deprescription of atorva-
statin and aspirin, which may reflect the belief that
potential risks like side effects outweighed potential ben-
efits of cardiovascular preventive medication in patients
with low CVD risk. This accords with the European
guidelines on preventing cardiovascular disease, which
recommend that patients with low CVD risk be given
lifestyle advice and not necessarily treated with antihy-
pertensives and/or lipid-lowering drugs [36, 37]. When
they decided which medication to deprescribe, GPs con-
sidered the risk/benefit of the medication, and the pa-
tient’s quality of life and life expectancy to be important.
Table 2 Comparison of percentages of GPs reporting to deprescribe medication in the case of a frail 82-year-old patient without
and with history of cardiovascular disease (CVD) and most frequently mentioned reasons to deprescribe for the case
History of CVD p-
value1No Yes
Medication Percentage of GPs
(95% CI)
Reasons to deprescribe (frequency) Percentage of GPs
(95% CI)
Reasons to deprescribe (frequency)
Atorvastatin
40 mg
100% - Not enough benefit (56)
- No indication (35)
- No evidence (16)
- Short estimated life expectancy (16)
76% (69–83%) - Not enough benefit (30)
- Other (25)
- Short estimated life expectancy (19)
< 0.001
Pantoprazole
20 mg
88% (83–93%) - No indication (111)
- In reserve, no long-term therapy (6)
- Not enough benefit (5)
81% (75–87%) - No indication (90)
- Not enough benefit (7)
0.002
Aspirin
100 mg
74% (67–81%) - No indication (55)
- Not enough benefit (19)
- Side effects (15)
32% (25–40%) - Other (13)
- Side effects (9)
- Short life expectancy (8)
< 0.001
Tramadol
50 mg
71% (63–78%) - Side effects (76)
- Lower drug dose (8)
- In reserve, no long-term therapy (8)
70% (63–77%) - Side effects (69)
- Lower drug dose (9)
- In reserve, no long-term therapy (8)
0.71
Amlodipine
5 mg
44% (36–52%) - No indication (22)
- Side effects (22)
- Not enough benefit (7)
- Deprescribe the drug and evaluate the
effect (7)
36% (28–44%) - No indication (21)
- Side effects (9)
- Other (7)
0.011
Paracetamol
1 g
29% (22–37%) - Lower drug dose (13)
- In reserve, no long-term therapy (13)
- Deprescribe the drug and evaluate the
effect (6)
29% (22–36%) - Lower drug dose (14)
- In reserve, no long-term therapy (10)
- Deprescribe the drug and evaluate the
effect (6)
0.56
Enalapril
10 mg
24% (17–31%) - No indication (15)
- Side effects (5)
- Lower drug dose (4)
19% (13–25%) - No indication (13)
- Lower drug dose (3)
- Other (3)
0.033
1P-value from McNemar’s test comparing percentages of GPs deprescribing each medication by CVD
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They also took the views and priorities of their patient
into account.
Strengths and limitations
Our study had a higher-than-usual survey response rate
(56% vs. the typical rate of 30–40%) [38] and our sample
closely matches the general Swiss population of GPs in
age, gender, and years in practice, but our results might
not be generalizable to GPs in other countries where pre-
scribing practices differ. The GPs we surveyed may have
been more interested in deprescribing than GPs in the
general population since our sample was taken from those
who had already consented to participate in research stud-
ies. Our study was also limited by the deliberate simplicity
of the case-vignettes we chose, since we were forced to
omit potentially interesting patient and GP characteristics.
For instance, the patient in the case-vignette has no
chronic health problems and takes no medicines associ-
ated with adverse drug events or that pose a risk when
deprescribed. But we deliberately chose this case-vignette
for the following reasons: 1) to standardize the case; 2) to
avoid overloading respondents with information, 3) to
make participation more feasible for GPs, and 4) to ensure
responders had a common understanding of the case. Our
analysis relied on claims GPs made about their intentions
(that they would deprescribe selected medications) but
these may not reflect their true practice. To mitigate this
problem, we used standardized case-vignettes to exemplify
a complex problem frequently encountered by GPs who
treat frail oldest-old patients with polypharmacy. A GP
who intends to describe may find that they cannot follow
through on the intention in clinical practice because they
are faced with barriers and factors outside their control.
Social desirability bias may also have affected our results;
for example, only 19% of respondents reported that time
was an important factor in deprescribing, though the
qualitative literature regularly reports time as a significant
barrier to deprescribing [20, 39]. But the anonymous na-
ture of the survey may have minimised this bias. Our
case-vignette may also have encouraged the GP to opt to
deprescribe, since the patient has impaired physical func-
tion and is likely to have limited life expectancy. In the vi-
gnette, the patient’s MMSE was 12 and he depended on
others for activities of daily living. Since dementia does
not progress predictably, and varies between individuals,
we could describe a patient with limited life expectancy,
but not be any more specific. If we told the GP the patient
was expected to live less than 12 months or needed pallia-
tive care, it might have changed our results [40, 41].
Comparison with existing literature
Our quantitative research complements qualitative find-
ings by Sinnige et al. [42], who assessed GPs’ medication
management strategy and factors that influenced the
deprescribing process in a similar setting. They also used
case-vignettes for hypothetical patients to understand how
GPs would deprescribe, identified patient- and medication-
related factors that influenced medication management
and highlighted the importance of taking a patient-centred
approach, considering the patient’s age and life expectancy,
and weighing patient’s preferences and perspectives into
the decision.
Our study accords with previous research that showed
CVD history influences GP prescribing decisions [33,
36]. We found higher rates of deprescribing statins than
did previous studies [43], perhaps because the patient in
our case-vignette was a nursing home resident. Depre-
scribing patterns might have been different in patients
with no or mild cognitive impairment [44]. Our case-vi-
gnette also provided sparse information about family
and caregiver involvement and advanced directives
might have facilitated deprescribing.
Ní Chróinín et al. [45] also used case-vignettes in a simi-
lar study of deprescription among geriatricians (N = 930,
response rate 14,4%). Like Ní Chróinín et al., we found
considerable willingness to deprescribe cardiovascular pre-
ventive medication in the scenario of cognitive impairment
and dependency. Ní Chróinín et al.’s sample included a
higher percentage of women and younger geriatricians
Table 3 Factors important to GPs (n = 157) when deprescribing
(per GP more than one answer was possible)
Factors Rated as very important
or important, %
Risk of a medication 99%
Benefit of a medication 98%
Quality of life of the patient 98%
Life expectancy of the patient 96%
Potential negative health outcomes of
medication’s change
76%
Interprofessional communication
(between GPs and other prescribing
physicians)
73%
Interprofessional collaboration
(between GPs and other prescribing
physicians)
72%
Age of the patient 73%
Existence of deprescribing guidelines 64%
Expectations of the patient 63%
Difficult communication (between GP and
patient, e.g. due to cognitive impairment)
56%
Expectation of relatives 49%
Existence of tools that facilitate deprescribing 48%
Expenditure of time for thinking about and
deprescribing in the older multimorbid
patient with polypharmacy
19%
Self-dispensation of medication in GP office1 7%
1Self-dispensation means ‘drug delivery by general practitioners in their office’
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than are present in the general population of GPs. Our
study population more closely matches the GP population
in age, gender, and years in practice, so our results suggest
these observations are more generally applicable.
Patients with dementia may be undertreated for pain [46,
47], possibly because members of this group express pain
differently than those without dementia (particularly if pa-
tients with dementia are non-verbal) [48]. Pain symptoms
like agitation or aggression may be attributed to dementia
(labelled behavioural and psychological symptoms of de-
mentia) and not treated appropriately [49]. It is thus unsur-
prising that GPs were less likely to deprescribe pain
medications, particularly paracetamol, than cardiovascular
medications. Since under-treatment of pain is a concern in
people with dementia, the proportion of GPs who would
deprescribe paracetamol (29%) when an individual has
chronic back pain may be higher than ideal, but 13/19 of
the GPs we surveyed would prescribe paracetamol as a re-
serve medication instead of eliminating it entirely. A high
proportion of GPs reported they would deprescribe trama-
dol, perhaps because of the risks the medication poses. Our
study was not designed to determine which medications
GPs would prescribe to best manage the patient’s pain (for
example, starting oxycodone instead of tramadol or initiat-
ing non-pharmacological management). GP’s deprescribing
patterns may also have been influenced by the results of re-
cent studies that found paracetamol and opioids might not
be effect for treating chronic pain [50, 51].
We found GPs heavily weighted the patient’s quality of
life and life expectancy, wishes and priorities, in their deci-
sions about deprescribing, perhaps because the patient in
the case vignette had advanced dementia. A focus on qual-
ity of life is a key part of modern medical care for people
with dementia [52]. Our findings complement those of re-
cently published reviews of patient barriers to and enablers
of deprescribing [53, 54] which emphasize the importance
of centring the deprescribing process on the patient [55].
Elements of patient-centred care include shared decision
making, viewing the person as a whole, and maintaining a
positive doctor-patient relationship [56]. But our study
was not designed to determine whether GPs felt able to
share decision-making about deprescribing, or how they
approached the discussion with patients. Other studies
found that GPs would appreciate guidelines or tools that
made it easier for them to deprescribe [14, 22, 39, 57]. The
Swiss GPs we included in our studies would welcome this
but did not prioritise it. Our findings also dovetail with re-
sults from qualitative studies that assessed why GPs decide
to deprescribe [20]. Our research suggests that Swiss GPs
would try to reduce medication burden in frail individuals
with multimorbidity and polypharmacy through depre-
scribing. However, while most responded that they regu-
larly dealt with the topic of deprescribing in practice, only
30% reported that they frequently deprescribed.
Implications for research and practice
We did not assess barriers to deprescribing (like fear of
negative consequences) in our case-vignette. Further clin-
ical trials are needed to measure the safety, benefits, and
best practices for deprescribing, especially in oldest-old
multimorbid patients. We also suggest researchers explore
more complex cases in the future by adding details to
case-vignettes. They may also wish to ask GPs about
deprescribing in a stable patient without current prob-
lems, to see if it changes the results. We hope others will
explore the reasons GPs prioritise or do not prioritise
reviewing medicines with an eye to deprescribing. Since
medication and patient characteristics are important fac-
tors in deprescribing, researchers should also study patient
and family beliefs and attitudes. If we knew more about
how, why, and when GPs decide to deprescribe, it should
be possible to develop tools that assist them in balancing
these (sometime competing) interests.
Conclusion
In case-vignettes, Swiss GPs were most likely to depre-
scribe cardiovascular preventive medication, citing lack
of indication and benefit, and less likely to deprescribe
pain medications. Overall, Swiss GPs expressed willing-
ness to deprescribe for frail oldest-old patients and were
guided in their decisions by the risks and benefits of a
medication, quality of life and life expectancy of patients,
and patient priorities.
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